Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Oral Atogepant for Prevention of Migraine
2023-507096-21-00Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of atogepant in migraine, chronic migraine, migraine with aura and 1 more, sponsored by AbbVie Inc. Primary endpoint: Percentage of participants with at least 1 treatment-emergent adverse event. Started Aug 2021; status: completed.
02
Drugs
atogepant
03
Conditions
migrainechronic migrainemigraine with auramigraine without aura
Beyond the preview
Go deeper on 2023-507096-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507096-21-00.